These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 35723820)

  • 21. Ocrelizumab: a B-cell depleting therapy for multiple sclerosis.
    Jakimovski D; Weinstock-Guttman B; Ramanathan M; Kolb C; Hojnacki D; Minagar A; Zivadinov R
    Expert Opin Biol Ther; 2017 Sep; 17(9):1163-1172. PubMed ID: 28658986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Ocrelizumab for treatment of multiple sclerosis].
    Graf J; Albrecht P; Goebels N; Aktas O; Hartung HP
    Nervenarzt; 2020 Aug; 91(8):722-734. PubMed ID: 32524163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Product review on MAbs (alemtuzumab and ocrelizumab) for the treatment of multiple sclerosis.
    Gabelić T; Barun B; Adamec I; Krbot Skorić M; Habek M
    Hum Vaccin Immunother; 2021 Nov; 17(11):4345-4362. PubMed ID: 34668842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rituximab treatment for multiple sclerosis.
    Ineichen BV; Moridi T; Granberg T; Piehl F
    Mult Scler; 2020 Feb; 26(2):137-152. PubMed ID: 31237800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects.
    Sorensen PS; Blinkenberg M
    Ther Adv Neurol Disord; 2016 Jan; 9(1):44-52. PubMed ID: 26788130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ocrelizumab extended-interval dosing in multiple sclerosis during SARS-CoV-2 pandemic: a real-world experience.
    Guerrieri S; Bucca C; Nozzolillo A; Genchi A; Zanetta C; Cetta I; Rugarli G; Gattuso I; Azzimonti M; Rocca MA; Moiola L; Filippi M;
    Eur J Neurol; 2023 Sep; 30(9):2859-2864. PubMed ID: 37227923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study.
    Alcalá C; Quintanilla-Bordás C; Gascón F; Sempere ÁP; Navarro L; Carcelén-Gadea M; Landete L; Mallada J; Cañizares E; Belenguer A; Carratalá S; Domínguez JA; Pérez-Miralles FC; Gil-Perotín S; Gasqué R; Cubas L; Castillo J; Casanova B
    J Neurol; 2022 Jul; 269(7):3676-3681. PubMed ID: 35107597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluating the efficacy and safety of Zytux
    Naser Moghadasi A; Darki A; Masoumi P; Hashemi SN; Ghadiri F
    Mult Scler Relat Disord; 2019 Nov; 36():101419. PubMed ID: 31586800
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability.
    Carlson AK; Amin M; Cohen JA
    Drugs; 2024 Mar; 84(3):285-304. PubMed ID: 38480630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management.
    Alvarez E; Longbrake EE; Rammohan KW; Stankiewicz J; Hersh CM
    Mult Scler Relat Disord; 2023 Nov; 79():105009. PubMed ID: 37783194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic.
    Zanghì A; Avolio C; Signoriello E; Abbadessa G; Cellerino M; Ferraro D; Messina C; Barone S; Callari G; Tsantes E; Sola P; Valentino P; Granella F; Patti F; Lus G; Bonavita S; Inglese M; D'Amico E
    Neurotherapeutics; 2022 Sep; 19(5):1535-1545. PubMed ID: 36036858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-world evaluation of ocrelizumab in multiple sclerosis: A systematic review.
    Montalban X; Matthews PM; Simpson A; Petrie JL; Sammon C; Ramagopalan S; Disanto G; Kuhle J
    Ann Clin Transl Neurol; 2023 Mar; 10(3):302-311. PubMed ID: 36728340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. B-Cell Therapies in Multiple Sclerosis.
    Sabatino JJ; Zamvil SS; Hauser SL
    Cold Spring Harb Perspect Med; 2019 Feb; 9(2):. PubMed ID: 29358322
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis.
    Starvaggi Cucuzza C; Longinetti E; Ruffin N; Evertsson B; Kockum I; Jagodic M; Al Nimer F; Frisell T; Piehl F
    Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36411076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibodies against CD20 (rituximab) for treating multiple sclerosis: US20100233121.
    Taupin P
    Expert Opin Ther Pat; 2011 Jan; 21(1):111-4. PubMed ID: 21155688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metronomic radiological surveillance in clinically stable MS patients on anti CD20 immunotherapy is redundant.
    Avasarala J
    Mult Scler Relat Disord; 2024 May; 85():105541. PubMed ID: 38457884
    [No Abstract]   [Full Text] [Related]  

  • 37. Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab.
    Auer M; Bsteh G; Hegen H; Wurth S; Zinganell A; Berger T; Deisenhammer F; Pauli FD
    Mult Scler Relat Disord; 2020 Aug; 43():102155. PubMed ID: 32470856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ublituximab: A new FDA-approved anti-CD20 mAb for relapsing forms of multiple sclerosis.
    Boldrini VO; Mader S; Kümpfel T; Meinl E
    Mult Scler Relat Disord; 2023 Jul; 75():104733. PubMed ID: 37156035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date.
    Ancau M; Berthele A; Hemmer B
    Expert Opin Biol Ther; 2019 Aug; 19(8):829-843. PubMed ID: 31027436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. It's not always an infection: Pyoderma gangrenosum of the urogenital tract in two patients with multiple sclerosis treated with rituximab.
    Parrotta E; Kopinsky H; Abate J; Ryerson LZ; Krupp LB
    Mult Scler Relat Disord; 2023 Feb; 70():104483. PubMed ID: 36580875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.